DK1536783T3 - Faste formuleringer, der omfatter en indolinonforbindelse - Google Patents

Faste formuleringer, der omfatter en indolinonforbindelse

Info

Publication number
DK1536783T3
DK1536783T3 DK03772489T DK03772489T DK1536783T3 DK 1536783 T3 DK1536783 T3 DK 1536783T3 DK 03772489 T DK03772489 T DK 03772489T DK 03772489 T DK03772489 T DK 03772489T DK 1536783 T3 DK1536783 T3 DK 1536783T3
Authority
DK
Denmark
Prior art keywords
solid formulations
indolinone compound
indolinone
compound
formulations
Prior art date
Application number
DK03772489T
Other languages
Danish (da)
English (en)
Inventor
Paolo Gatti
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1536783(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of DK1536783T3 publication Critical patent/DK1536783T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK03772489T 2002-09-10 2003-09-10 Faste formuleringer, der omfatter en indolinonforbindelse DK1536783T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42113302P 2002-09-10 2002-09-10
PCT/IB2003/005293 WO2004024127A2 (en) 2002-09-10 2003-09-10 Solid formulations comprising an indolinone compound

Publications (1)

Publication Number Publication Date
DK1536783T3 true DK1536783T3 (da) 2008-10-13

Family

ID=31994326

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03772489T DK1536783T3 (da) 2002-09-10 2003-09-10 Faste formuleringer, der omfatter en indolinonforbindelse

Country Status (31)

Country Link
US (1) US20040229930A1 (nl)
EP (1) EP1536783B2 (nl)
JP (1) JP2006503032A (nl)
KR (1) KR20050059170A (nl)
CN (1) CN1688304A (nl)
AR (1) AR041193A1 (nl)
AT (1) ATE403425T1 (nl)
AU (1) AU2003280108B2 (nl)
BR (1) BR0314182A (nl)
CA (1) CA2498415C (nl)
DE (1) DE60322720D1 (nl)
DK (1) DK1536783T3 (nl)
DO (1) DOP2003000708A (nl)
ES (1) ES2309363T5 (nl)
GT (1) GT200300193A (nl)
HN (1) HN2003000272A (nl)
MX (1) MXPA05002690A (nl)
MY (1) MY136767A (nl)
NL (1) NL1024261C (nl)
NO (1) NO20051670L (nl)
NZ (1) NZ538636A (nl)
PA (1) PA8581801A1 (nl)
PE (1) PE20040989A1 (nl)
PL (1) PL375978A1 (nl)
PT (1) PT1536783E (nl)
RU (1) RU2005110663A (nl)
SI (1) SI1536783T1 (nl)
TW (1) TW200418836A (nl)
UY (1) UY27969A1 (nl)
WO (1) WO2004024127A2 (nl)
ZA (1) ZA200501897B (nl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004277464B2 (en) * 2003-10-02 2010-07-08 Pharmacia & Upjohn Company Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
KR20080040007A (ko) * 2005-09-20 2008-05-07 화이자 프로덕츠 인크. 티로신 키나제 억제제를 이용한 치료의 투여형 및 방법
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
KR20100069705A (ko) * 2007-11-21 2010-06-24 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 헤미-ｌ-말레이트, 이의 다형 및 제조 방법, 라세미 수니티닙 말레이트의 다형, 수니티닙 염기 및 말산을 함유하는 조성물 및 이의 제조 방법
EA201001125A1 (ru) * 2008-02-13 2011-04-29 Рациофарм Гмбх Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2373642A2 (en) 2008-07-24 2011-10-12 Teva Pharmaceutical Industries Ltd Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
WO2010039798A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN103301116A (zh) * 2012-03-16 2013-09-18 大鹏药品工业株式会社 口服医药组合物
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
KR102196884B1 (ko) 2013-11-01 2020-12-30 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
CN113597301A (zh) * 2019-01-09 2021-11-02 细胞基因公司 包含(s)-4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的药物组合物以及使用它的方法
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
ES2367007T3 (es) * 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
DE19956598A1 (de) * 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
SK287142B6 (sk) * 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
UA76483C2 (en) * 2001-08-15 2006-08-15 Upjohn Co Crystalline form of malic acid salt of n-|2-(diethylamino)ethyl|-5-|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds

Also Published As

Publication number Publication date
BR0314182A (pt) 2005-08-09
PT1536783E (pt) 2008-10-10
SI1536783T1 (sl) 2008-12-31
ATE403425T1 (de) 2008-08-15
KR20050059170A (ko) 2005-06-17
US20040229930A1 (en) 2004-11-18
RU2005110663A (ru) 2005-09-10
CN1688304A (zh) 2005-10-26
PA8581801A1 (es) 2005-02-04
UY27969A1 (es) 2004-04-30
NZ538636A (en) 2006-04-28
NL1024261A1 (nl) 2004-03-11
MXPA05002690A (es) 2005-05-05
WO2004024127A3 (en) 2004-06-03
EP1536783B2 (en) 2011-08-24
AU2003280108A1 (en) 2004-04-30
MY136767A (en) 2008-11-28
JP2006503032A (ja) 2006-01-26
CA2498415C (en) 2007-05-29
ZA200501897B (en) 2005-09-07
DE60322720D1 (de) 2008-09-18
WO2004024127A2 (en) 2004-03-25
PE20040989A1 (es) 2004-12-28
NL1024261C (nl) 2010-04-06
CA2498415A1 (en) 2004-03-25
EP1536783A2 (en) 2005-06-08
ES2309363T5 (es) 2011-12-07
PL375978A1 (en) 2005-12-12
GT200300193A (es) 2004-04-29
ES2309363T3 (es) 2008-12-16
TW200418836A (en) 2004-10-01
EP1536783B1 (en) 2008-08-06
AU2003280108B2 (en) 2007-04-05
DOP2003000708A (es) 2004-03-31
HN2003000272A (es) 2008-07-29
AR041193A1 (es) 2005-05-04
NO20051670L (no) 2005-04-04

Similar Documents

Publication Publication Date Title
DK1536783T3 (da) Faste formuleringer, der omfatter en indolinonforbindelse
DE60336314D1 (de) Substituierte indole
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DE60318890D1 (de) Mandelsäure derivate
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
NO20052239D0 (no) Fast preparat
DE602004024770D1 (de) Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
IS7793A (is) Nýtt efnasamband
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
DE60324703D1 (de) Barbitursäure derivaten.
ITMI20022602A1 (it) Scatola di derivazione perfezionata, particolarmente
ES1051856Y (es) Burlete perfeccionado.
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
ES1050965Y (es) Decantador perfeccionado.
ES1051803Y (es) Andamio perfeccionado.
ES1049590Y (es) Cenicero ambientador perfeccionado.
ES1048757Y (es) Calzado perfeccionado.
ES1051038Y (es) Sofa perfeccionado.
ES1051713Y (es) Sobre-nota perfeccionado.
ES1051515Y (es) Estuche perfeccionado.
ES1052103Y (es) Cartera-monedero perfeccionada.
ES1051008Y (es) Trebedes perfeccionadas.
ES1051947Y (es) Carpeta-archivador perfeccionada.
ES1051560Y (es) Avisador perfeccionado.